navarixin (MK-7123) / Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 12 Diseases   2 Trials   2 Trials   54 News 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
navarixin (MK-7123) / Merck (MSD)
ACTRN12610000345088: A Dose-Ranging Study of the Effects of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Recruiting
2
500
 
Schering-Plough, Schering-Plough
Moderate to Severe Chronic Obstructive Pulmonary Disease
 
 
ACTRN12609000661279: A Study to Further Understand the Effects of SCH 527123 on Tissue Neutrophils

Recruiting
N/A
23
 
Schering-Plough, Schering-Plough
for Chronic Obstructive Pulmonary Disease(COPD) - the tolerability and safety of 100 mg SCH 527123 in healthy subjects, for Chronic Obstructive Pulmonary Disease(COPD) - the dose-response relationship of effects of SCH 527123 on neutrophils in the oral mucosa in healthy volunteers, as a determinant of neutrophil response while using study drug
 
 

Download Options